Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rescigno

Showing results (621-630 of 1,117) with videos related to

Pageof 112
Sort By:
Scientific Reports|August 26, 2024
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world studyMimma Rizzo, Andrey Soares, Enrique Grande, et al.
Cancer Immunology, Immunotherapy : CII|July 2, 2024
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 studyCarlo Messina, Martina Catalano, Giandomenico Roviello, et al.
European Urology|September 16, 2022
B7-H3 as a Therapeutic Target in Advanced Prostate CancerChristina Guo, Ines Figueiredo, Bora Gurel, et al.
Frontiers in Oncology|August 11, 2025
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 studyMaria T Bourlon, Luca Galli, Enrique Grande, et al.
Gut|November 18, 2025
Intestinal blood vessel-associated macrophages and gut-vascular barrier dysfunction in cirrhosisLena Smets, Maria Francesca Viola, Markus Boesch, et al.
Cancer Cell|November 22, 2024
Elucidating acquired PARP inhibitor resistance in advanced prostate cancerGeorge Seed, Nick Beije, Wei Yuan, et al.
Nature Medicine|October 31, 2019
Author Correction: Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradationAndrew Maltez Thomas, Paolo Manghi, Francesco Asnicar, et al.
Frontiers in Oncology|February 27, 2024
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: <i>post-hoc</i> analysis of the Meet-URO 15 studyVeronica Murianni, Alessio Signori, Sebastiano Buti, et al.
Nature Medicine|April 3, 2019
Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradationAndrew Maltez Thomas, Paolo Manghi, Francesco Asnicar, et al.
Cancer Immunology, Immunotherapy : CII|May 27, 2025
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)Matteo Santoni, Giandomenico Roviello, Enrique Grande, et al.
Pageof 112

Showing results (621-630 of 1,117) with videos related to

Sort By:
Pageof 112
Scientific Reports|August 26, 2024
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world studyMimma Rizzo, Andrey Soares, Enrique Grande, et al.
Cancer Immunology, Immunotherapy : CII|July 2, 2024
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 studyCarlo Messina, Martina Catalano, Giandomenico Roviello, et al.
European Urology|September 16, 2022
B7-H3 as a Therapeutic Target in Advanced Prostate CancerChristina Guo, Ines Figueiredo, Bora Gurel, et al.
Frontiers in Oncology|August 11, 2025
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 studyMaria T Bourlon, Luca Galli, Enrique Grande, et al.
Gut|November 18, 2025
Intestinal blood vessel-associated macrophages and gut-vascular barrier dysfunction in cirrhosisLena Smets, Maria Francesca Viola, Markus Boesch, et al.
Cancer Cell|November 22, 2024
Elucidating acquired PARP inhibitor resistance in advanced prostate cancerGeorge Seed, Nick Beije, Wei Yuan, et al.
Nature Medicine|October 31, 2019
Author Correction: Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradationAndrew Maltez Thomas, Paolo Manghi, Francesco Asnicar, et al.
Frontiers in Oncology|February 27, 2024
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: <i>post-hoc</i> analysis of the Meet-URO 15 studyVeronica Murianni, Alessio Signori, Sebastiano Buti, et al.
Nature Medicine|April 3, 2019
Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradationAndrew Maltez Thomas, Paolo Manghi, Francesco Asnicar, et al.
Cancer Immunology, Immunotherapy : CII|May 27, 2025
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)Matteo Santoni, Giandomenico Roviello, Enrique Grande, et al.
Pageof 112